Search clinical trials for: QR-010

Total 3862 results

ProQR Therapeutics
European Commission

Completed

Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation

Cystic Fibrosis

United States, France, Belgium
ProQR Therapeutics
European Commission

Completed

Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients

Cystic Fibrosis

United States, Spain, United Kingdom, Germany, Italy, Belgium, Canada, Czechia, Denmark, France
ProQR Therapeutics

Terminated

Extension Study to Study PQ-110-001 (NCT03140969) (INSIGHT)

Eye Diseases | Neurologic Manifestations | Eye Diseases, Hereditary | Sensation Disorders | Vision Disorders | Blindness | Leber Congenital Amaurosis | Leber Congenital Amaurosis 10 | Retinal Disease | Eye Disorders Congenital

United States, Belgium
ProQR Therapeutics

Recruiting

An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene. (BRIGHTEN)

Eye Diseases | Neurologic Manifestations | Retinal Degeneration | Retinal Dystrophies | Sensation Disorders | Vision Disorders | Blindness | Leber Congenital Amaurosis | Leber Congenital Amaurosis 10 | Retinal Disease | Eye Disorders Congenital

Belgium, Brazil, Canada, Germany, Italy, Netherlands, United Kingdom
ProQR Therapeutics

Completed

Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene

Leber's Congenital Amaurosis

United States, Belgium
ProQR Therapeutics

Active, not recruiting

A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) (ILLUMINATE)

Eye Diseases | Neurologic Manifestations | Eye Diseases, Hereditary | Sensation Disorders | Vision Disorders | Blindness | Leber Congenital Amaurosis | Leber Congenital Amaurosis 10 | Retinal Disease | Eye Disorders Congenital

United States, Belgium, Brazil, Canada, France, Germany, Italy, Netherlands, United Kingdom
Quigley Pharma, Inc.

Completed

Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy

Diabetic Neuropathy

United States
ProQR Therapeutics

Withdrawn

Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3 (Fuchs Focus)

Corneal Diseases | Fuchs Endothelial Corneal Dystrophy | FECD3 | LRS | Descemet's Membrane Disorder

United Kingdom
Phoenicis Therapeutics

Terminated

A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene

Epidermolysis Bullosa Dystrophica, Recessive | Epidermolysis Bullosa Dystrophica, Dominant

United States, Spain, France
ProQR Therapeutics

Active, not recruiting

A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene (AURORA)

Eye Diseases | Retinitis | Eye Diseases, Hereditary | Retinal Dystrophies | Vision Disorders | Retinal Disease | Autosomal Dominant Retinitis Pigmentosa | Vision Tunnel

United States
Kocaeli University

Completed

Preterm Newborn Mothers' Anxiety and Self-Efficacy

Education | Mother-Infant Interaction | Nursing Care

Turkey
ProQR Therapeutics

Terminated

Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)

Eye Diseases | Retinitis Pigmentosa | Eye Diseases, Hereditary | Vision Disorders | Retinal Disease | Eye Disorders Congenital | Usher Syndrome Type 2 | Deaf Blind

United States, United Kingdom
Sakarya University

Not yet recruiting

Effect of Breastfeeding Training (Breastfeeding)

Breastfeeding

Turkey
Prolacta Bioscience

Recruiting

Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation

Hematologic Malignancy

United States
Pendulum Therapeutics

Completed

Placebo-Controlled Clinical Nutrition Study of the Safety and Metabolic Effects of Two Medical Foods in Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
Guangzhou Gloria Biosciences Co., Ltd.

Recruiting

Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors

Solid Tumor

China
ProQR Therapeutics

Completed

Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Stellar)

Eye Diseases | Retinitis Pigmentosa | Eye Diseases, Hereditary | Vision Disorders | Retinal Disease | Eye Disorders Congenital | Usher Syndrome Type 2 | Deaf Blind

United States, Canada, France
Guangzhou Gloria Biosciences Co., Ltd.

Not yet recruiting

Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer

Advanced Non-Small Cell Lung Cancer

China
University of North Carolina, Chapel Hill

Completed

Analysis of Orthodontic Tooth Movement Using 3D Imaging

Malocclusion | Tooth Crowding | Dental Crowding

United States
Pieris Pharmaceuticals GmbH
FGK Clinical Research GmbH; Nuvisan Pharma Services; EUROCALIN Consortium

Completed

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRS-080

Healthy

Germany
University of North Carolina, Chapel Hill
American Diabetes Association

Completed

Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM

Overweight and Obesity | Eating Behavior

United States
University of British Columbia

Completed

Mannitol Cream for Post Herpetic Neuralgia (MannitolPHN)

Neuralgia, Postherpetic

Canada
Contera Pharma
Bukwang Pharmaceutical

Active, not recruiting

A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia (ASTORIA)

Dyskinesias

France, Germany, Italy, Korea, Republic of, Spain
BlueWillow Biologics
Porton Biopharma Ltd.

Completed

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults (IN NE-rPA)

Anthrax

United States
Synthetic Biologics Inc.

Completed

A Study of the Effect of SYN-010 on Subjects With IBS-C

Irritable Bowel Syndrome With Constipation (IBS-C)

United States
Guangzhou Gloria Biosciences Co., Ltd.

Not yet recruiting

GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)

Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma | Classic Hodgkin's Lymphoma
Biocad

Recruiting

A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A (EDELWEISS)

Hemophilia A

Russian Federation
Cryonove Pharma
CEISO; Dermatech; LTD HEALTH

Completed

Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots

Lentigo Solar

Georgia
Cryonove Pharma
CEISO; Dermatech; Sefako Makgatho Health Sciences University

Completed

Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots.

Solar Lentigo | Post-inflammatory Hyperpigmentation | Senile Lentigo

South Africa
Alexza Pharmaceuticals, Inc.
Celerion

Completed

Staccato® Granisetron Multiple Dose PK

Healthy

United States
Pieris Pharmaceuticals GmbH
FGK Clinical Research GmbH

Completed

Phase 2a Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients

Anemia of Chronic Kidney Disease

Czechia, Germany
Pieris Pharmaceuticals GmbH
FGK Clinical Research GmbH

Unknown

Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients

Anemia of Chronic Kidney Disease

Germany
Hutchison Medipharma Limited

Completed

A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion of [14C]Sulfatinib

Healthy

China
Genentech, Inc.

Completed

A Pharmacokinetic Study of [14C]-GDC-0810 After Single Oral Administration in Healthy Female Participants

Healthy Volunteers

United States
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD

Attention Deficit Disorder With Hyperactivity

United States
Orthopus
Handicap International

Recruiting

Study of the Social and Professional Reintegration Improvements Using a Set of Solutions for Upper Limb Amputation

Wounds and Injuries | Amputation; Traumatic, Arm, Upper | Amputation; Traumatic, Hand, at Wrist Level | Amputation; Traumatic, Arm: Forearm

Nepal
Orca Therapeutics B.V.
CMX Research

Active, not recruiting

First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients.

Adenocarcinoma of the Prostate

Canada
BioMimetix JV, LLC

Suspended

Evaluation of Topical Application of BMX-010 in Subjects With Rosacea

Rosacea

United States
Tianjin Chasesun Pharmaceutical Co., LTD

Enrolling by invitation

A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors

Malignant Neoplasms

China
Synthetic Biologics Inc.

Completed

A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-C

Irritable Bowel Syndrome With Constipation (IBS-C)

United States
Mallinckrodt

Terminated

Trial to Study the Safety of Intravenous MNK-010 in Advanced Solid Tumors

Advanced Solid Tumors

United States
Contera Pharma A/S

Not yet recruiting

Open-Label Extension Study of ASTORIA

Dyskinesias
National Cancer Institute (NCI)

Terminated

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma

Mesothelioma

United States
Bukwang Pharmaceutical

Active, not recruiting

Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components (SHINE)

Parkinson Disease | Dyskinesias

United States
University of British Columbia

Completed

Topical Menthol +/- Mannitol for Painful Diabetic Peripheral Neuropathy

Diabetic Peripheral Neuropathy

Canada
ImmunoRx Pharma Inc.

Recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy Participants

Healthy Participants

Netherlands
BioMimetix JV, LLC

Terminated

Evaluation of Topical Application of BMX-010 in Subjects With Acne Vulgaris.

Acne Vulgaris

United States
BioMimetix JV, LLC

Completed

Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis

Psoriasis | Atopic Dermatitis

United States
BioMimetix JV, LLC
Innovaderm Research Inc.

Terminated

A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis

Atopic Dermatitis

United States
Hoffmann-La Roche

Completed

A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies

Solid Tumors, Advanced Solid Tumors

United States

Search clinical trials for: QR-010

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations